ravive, Inc. (NASDAQ:ARAV, ", the Company", ))))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.
Asia Mostly Up, Europe Markets Gain In Anticipation Of US Inflation Data, Crude Nears $80 – Global Markets Today While US Was Sleeping
On Monday, November 13th, the U.S. stock markets closed mixed as investors awaited key inflation data that might shed light on the duration of the U.S. Federal Reserve's high-interest rate policy.
In the 11 key sectors of the S&P 500, energy emerged as the top performer, while utilities experienced the largest decline.
